文献速递腹部CT

CT放射组学预测肝细胞癌MTM亚型及免疫状态

CT Radiomics to Predict Macrotrabecular-Massive Subtype and Immune Status in Hepatocellular Carcinoma.
PubMed 文献 · Radiology · 2022-12-13

本研究基于三个中心365例切除肝细胞癌患者的术前增强CT构建放射组学模型,预测MTM亚型,训练集、内部测试集和外部测试集AUC分别为0.84、0.80和0.74。

要点

  • CT放射组学模型可无创预测HCC的MTM亚型,外部测试AUC为0.74。
  • 模型评分较低与接受TACE联合抗血管生成治疗患者更长的PFS独立相关。
  • 模型预测的MTM亚型与B细胞浸润和免疫球蛋白合成失调相关。

核心结论

  • CT放射组学模型能较准确预测肝细胞癌MTM亚型,且模型评分与体液免疫缺陷及进展生存期相关。

研究设计与样本

  • 回顾性多中心研究,纳入2015年1月至2021年12月三个学术医疗中心的365例成人切除HCC患者,分为训练集、内部测试集和外部测试集。
  • 使用术前肝脏增强CT提取放射组学特征,通过机器学习构建模型,并在两个测试集验证。
  • 结局队列纳入58例接受TACE和抗血管生成治疗的晚期HCC患者,评估模型对PFS的预测价值。
  • 利用TCGA中41例肿瘤的bulk RNA测序和7例前瞻性入组患者的单细胞RNA测序探究免疫浸润模式。

诊断标准与关键数值

  • 放射组学模型包含11个放射组学特征,预测MTM亚型的AUC在训练集为0.84、内部测试集为0.80、外部测试集为0.74。

临床应用与阅片要点

  • 对于拟行手术或TACE的HCC患者,可考虑术前增强CT放射组学分析辅助无创识别MTM亚型。
  • 模型评分较低可能提示较好预后,但需结合临床和其他影像特征综合判断。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background Macrotrabecular-massive (MTM) subtype of hepatocellular carcinoma (HCC) is an aggressive variant associated with angiogenesis and immunosuppressive tumor microenvironment, which is expected to be noninvasively identified using radiomics approaches. Purpose To construct a CT radiomics model to predict the MTM subtype and to investigate the underlying immune infiltration patterns. Materials and Methods This study included five retrospective data sets and one prospective data set from three academic medical centers between January 2015 and December 2021. The preoperative liver contrast-enhanced CT studies of 365 adult patients with resected HCC were evaluated. The Third Xiangya Hospital of Central South University provided the training set and internal test set, while Yueyang Central Hospital and Hunan Cancer Hospital provided the external test sets. Radiomic features were extracted and used to develop a radiomics model with machine learning in the training set, and the performance was verified in the two test sets. The outcomes cohort, including 58 adult patients with advanced HCC undergoing transarterial chemoembolization and antiangiogenic therapy, was used to evaluate the predictive value of the radiomics model for progression-free survival (PFS). Bulk RNA sequencing of tumors from 41 patients in The Cancer Genome Atlas (TCGA) and single-cell RNA sequencing from seven prospectively enrolled participants were used to investigate the radiomics-related immune infiltration patterns. Area under the receiver operating characteristics curve of the radiomics model was calculated, and Cox proportional regression was performed to identify predictors of PFS. Results Among 365 patients (mean age, 55 years ± 10 [SD]; 319 men) used for radiomics modeling, 122 (33%) were confirmed to have the MTM subtype. The radiomics model included 11 radiomic features and showed good performance for predicting the MTM subtype, with AUCs of 0.84, 0.80, and 0.74 in the training set, internal test set, and external test set, respectively. A low radiomics model score relative to the median value in the outcomes cohort was independently associated with PFS (hazard ratio, 0.4; 95% CI: 0.2, 0.8; P = .01). The radiomics model was associated with dysregulated humoral immunity involving B-cell infiltration and immunoglobulin synthesis. Conclusion Accurate prediction of the macrotrabecular-massive subtype in patients with hepatocellular carcinoma was achieved using a CT radiomics model, which was also associated with defective humoral immunity. Published under a CC BY 4.0 license. Supplemental material is available for this article. See also the editorial by Yoon and Kim in this issue.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Feng, Li, Liu, et al. CT Radiomics to Predict Macrotrabecular-Massive Subtype and Immune Status in Hepatocellular Carcinoma. Radiology. 2022. PMID: 36511807. doi:10.1148/radiol.221291

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。